ClinicalTrials.gg
CompletedNCT04666129Updated Aug 17, 2025

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

A Phase 1 interventional study of Relugolix and Abiraterone in Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-Sensitive Prostate Cancer and Non-Metastatic Castration-Resistant Prostate Cancer, sponsored by Sumitomo Pharma America, Inc.. Completed at 16 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-17.

Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2024, 2 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 126 studies testing abiraterone in Prostatic Neoplasms — 17 open to participants now, 37 under way, 5 of them phase 3. abiraterone · Prostatic Neoplasms.

Enrollment
67th of 126
48 · median 51
Started
2021
with 10 others
Phase 1
20 of 126
none open now
Registered
96th of 126
by date

Among the 126 studies testing abiraterone in Prostatic Neoplasms, this one is the 67th largest by enrollment, is one of 11 that started in 2021, is one of 20 in phase 1, and was the 96th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

17 of the 126 studies testing abiraterone in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About abiraterone

abiraterone: first FDA approval 2011 (ZYTIGA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies testing abiraterone in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This study is being conducted to assess the safety and tolerability of relugolix with other agents approved for use in combination with androgen deprivation therapy (ADT) for a 12-week treatment period and an additional 40-week safety extension period in men with prostate cancer, either metastatic castration-sensitive prostate cancer (mCSPC) or non-metastatic or metastatic castration-resistant prostate cancer (nmCRPC or mCRPC).

Read the detailed description

This is a three-part, open-label, parallel-cohort study to assess the safety and tolerability of relugolix as the ADT component in combination treatment with abiraterone acetate plus a corticosteroid in patients with mCSPC or mCRPC (Part 1), apalutamide in patients with mCSPC or nmCRPC (Part 2), or docetaxel with or without prednisone in patients with mCSPC or mCRPC (Part 3).

The study will consist of a 45-day screening period followed by a 12-week treatment period with one of the three combination treatments (Parts 1, 2, or 3). All participants are required to be currently or previously treated with a GnRH receptor antagonist (analog), leuprolide acetate or triptorelin, or a GnRH receptor antagonist, degarelix or relugolix, in combination with either abiraterone plus prednisone (Part 1), apalutamide (Part 2), or docetaxel (Part 3). The study consists of a 12-week primary study treatment period in which safety and tolerability, including assessment of vital sign measurements, ECGs, clinical laboratory tests and reporting of adverse events every 2 to 4 weeks, followed by a 40-week safety extension treatment period during which adverse events and changes to concomitant medications will be reported. The total treatment duration is 52 weeks.

03

Conditions studied

  • Metastatic Castration-Resistant Prostate Cancer
  • Metastatic Castration-Sensitive Prostate Cancer
  • Non-Metastatic Castration-Resistant Prostate Cancer

Browse trials for

Keywords

  • mCRPC
  • mCSPC
  • Relugolix
  • Abiraterone
  • Prednisone
  • Leuprolide acetate
  • nmCRPC
  • Apalutamide
  • Docetaxel
  • Degarelix
  • Methylprednisolone
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. A previous diagnosis of adenocarcinoma of the prostate confirmed by histologic or cytologic evidence and with a documented medical history of either:

    • mCSPC (Parts 1, 2, and 3) defined as having at least two of three risk factors at the baseline (Day 1) visit:

      • Total Gleason score of ≥ 6; and
      • Presence of ≥ 2 lesions on bone scan; OR
      • Radiologic evidence of measurable visceral metastases with exception of hepatic metastases.
    • nmCRPC (Part 2 only) defined as disease progression despite maintaining castration levels of testosterone with androgen deprivation therapy (ADT), as evidenced by an increase in consecutive prostate-specific antigen (PSA) concentrations (2 measurements, at least one week apart).
    • mCRPC (Parts 1 and 3) defined as disease progression despite maintaining castration levels of testosterone with ADT:

      • An increase in consecutive PSA (2 measurements at least 1 week apart); or
      • Worsening clinical symptoms; or
      • Radiologic evidence demonstrating enlarged metastatic lesions or the development of new metastases.
  2. Initiating treatment or currently receiving treatment of leuprolide acetate (3-, 4-, or 6-month injections [intramuscular Lupron or subcutaneous Eligard]) or another GnRH receptor agonist (triptorelin) or a GnRH receptor antagonist (degarelix or relugolix [maximum duration of 3 months]) in combination with:

    • Part 1: abiraterone acetate 1000 mg or fine-particle abiraterone acetate 500 mg once daily plus prednisone 5 mg once daily for participants with mCSPC or twice daily for participants with mCRPC or methylprednisolone 4 mg once daily and in whom abiraterone has been well tolerated (that is, without evidence of hepatotoxicity requiring dose adjustment for abiraterone).
    • Part 2: apalutamide 240 mg once daily and in whom apalutamide has been well tolerated (that is, without a fracture, fall, or seizure episode or need to dose adjust due to any adverse events).
    • Part 3: docetaxel 75 mg/m2 and in whom docetaxel has been well tolerated (that is, no evidence of reaction, febrile neutropenia or neutrophils \< 500 cells/mm3 for more than 1 week, severe or cumulative cutaneous reactions, or moderate neurosensory signs and/or symptoms despite dose reduction). Note: Patients receiving treatment with another agent in addition to docetaxel, such as a synthesis inhibitor or androgen receptor antagonist, may be enrolled.

Key Exclusion Criteria:

A patient will not be eligible for inclusion in the study if any of the following criteria apply:

  1. A medical history of brain or hepatic metastases based on radiologic evidence or a medical history of surgical castration;
  2. Received combination treatment with a GnRH analog or GnRH receptor antagonist with either abiraterone acetate plus a corticosteroid (Part 1) or apalutamide (Part 2) in patients with mCSPC (Part 1 and Part 2) or nmCRPC (Part 2) for a total duration > 24 months or in patients with mCRPC (Part 1) for a total duration > 6 months;
  3. Is scheduled or anticipates being scheduled for major surgery during the study treatment period;
  4. A current diagnosis of a other than prostate cancer, with the exception of any of the following:

    • Adequately treated basal cell carcinoma or squamous cell carcinoma of the skin, or carcinoma in situ of any type;
    • Adequately treated Stage I cancer that is currently in remission and has been in remission for ≥ 2 years;
    • Any other cancer from which the patient has been disease-free for ≥ 3 years;
  5. Abnormal clinical laboratory test value(s) at the screening visit or prior to the baseline (Day 1) visit including:

    • Serum creatinine > 2.0 mg/dL;
    • \< 100 × 103/μL;
    • \< 10.0 g/dL;
    • Leukocytes (WBC) \< 3 × 103/μL;
    • \< 1.5 × 103/μL;
    • (HbA1c) > 8%; Note (Part 3 only): Transfusions and/or administration of growth factors are permitted as indicated for the clinical management of docetaxel-related hematologic effects and in accordance with the investigator's judgement.
  6. Known hepatic disease, including alcoholic liver disease or viral hepatitis such as hepatitis A (hepatitis A virus IgM positive), chronic (HbsAg positive), or chronic (HCV antibody positive, confirmed by HCV RNA) or clinical signs of hepatic disease such as jaundice;
  7. A medical history within 6 months prior to the screening visit or a current diagnosis of any of the following:

    • Myocardial infarction;
    • Unstable angina;
    • Unstable symptomatic ischemic heart disease;
    • Congestive heart failure classified as class III or IV heart failure;
    • Thromboembolic event(s) (eg, deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular event[s]);
    • Any other significant cardiac condition (eg, pericardial effusion, restrictive cardiomyopathy, severe untreated valvular stenosis, or severe congenital heart disease);
  8. An abnormal ;
  9. Uncontrolled hypertension;
  10. Hypotension;
  11. Bradycardia;
  12. Positive ;
  13. Medical history of a bleeding disorder or current clinical evidence of gastrointestinal bleeding or active bleeding from another anatomical location;
  14. A medical history within 1 year of the screening visit of drug or alcohol abuse disorder according to V;
  15. Received an drug within 28 days or 5 half-lives, whichever is longer, prior to the baseline (Day 1) visit;
  16. Prior use of any prohibited medication(s) and restrictive medication(s) without the appropriate or use of a prohibited medication during the study treatment period is planned;
  17. A or known history of hypersensitivity to any of the study treatments or components thereof, or has a history of drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates study participation;
  18. Any other medical or psychiatric condition that, in the opinion of the investigator, would interfere with accomplishing the study objectives or the patient completing the study;
  19. Is a study site employee or is a primary family member (spouse, parent, child, or sibling) of a site employee involved in the conduct of the study.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Part 1: Relugolix plus Abiraterone plus a Corticosteroid

    Participants will receive relugolix in combination with abiraterone plus a corticosteroid for 12 weeks during the study treatment period.

    Drug: Relugolix · Drug: Abiraterone · Drug: Prednisone · Drug: Methylprednisolone

  • Experimental
    Part 2: Relugolix plus Apalutamide

    Participants will receive relugolix in combination with apalutamide for 12 weeks during the study treatment period.

    Drug: Relugolix · Drug: Apalutamide

  • Experimental
    Part 3: Relugolix plus Docetaxel with or without Prednisone

    Participants will receive relugolix in combination with docetaxel with or without prednisone for 12 weeks during the study treatment period.

    Drug: Relugolix · Drug: Prednisone · Drug: Docetaxel

Interventions

  • (Part 1 and Part 3) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 120-mg dose (1 x 120-mg tablets), taken once daily at approximately the same time each day. (Part 2) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 240-mg dose (2 x 120-mg tablets), taken once daily at approximately the same time each day.

    Also known as: MVT-601, TAK-385, T-1331285, RVT-601, Orgovyx

  • Abiraterone acetate (1000 mg \[2 x 500-mg tablets\]) or fine-particle abiraterone acetate (500 mg \[4 x 125-mg tablets\]) will be administered orally once daily.

    Also known as: Zytiga, Yonsa

  • (Part 1 only) For participants with mCSPC, a 5-mg dose of prednisone will be administered orally once daily, and for participants with mCRPC, a 5-mg dose of prednisone will be administered orally twice daily. (Part 3 only) Prednisone 5 mg can be administered orally twice daily but is not required.

  • For participants with mCRPC taking fine-particle abiraterone acetate, methylprednisolone 4 mg will be administered orally twice daily.

    Also known as: Medrol

  • Apalutamide 240 mg (4 x 60-mg tablets) will be administered orally once daily.

    Also known as: Erleada

  • Docetaxel 75 mg/m2 dose will be administered every 3 weeks as a 1-hour intravenous infusion.

    Also known as: Docefrez, Taxotere

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events

    Parts 1, 2, and 3

    Time frame: Baseline through Week 13

Secondary outcomes

  1. Mean Testosterone Serum Concentrations at Baseline (Day 1), Week 5, and Week 13

    Parts 1 and 2

    Time frame: Baseline (Day 1), Week 5, and Week 13

  2. Number and Proportion of Participants with Testosterone Concentrations ≥ 50 ng/dL at Baseline (Day 1), Week 5, and Week 13

    Parts 1 and 2

    Time frame: Baseline (Day 1), Week 5, and Week 13

  3. Relugolix Trough Concentrations at Baseline (Day 1), Week 3, Week 5, Week 9, and Week 13

    Part 2

    Time frame: Baseline (Day 1), Week 3, Week 5, Week 9, and Week 13

  4. Apalutamide and N-desmethyl Apalutamide Trough Concentrations at Baseline (Day 1), Week 3, Week 5, Week 9, and Week 13

    Part 2

    Time frame: Baseline (Day 1), Week 3, Week 5, Week 9, and Week 13

  5. Mean Testosterone Serum Concentrations at Baseline (Day 1), Mid-Treatment, and Week 13

    Part 3

    Time frame: Baseline (Day 1), Mid-Treatment, and Week 13

  6. Number and Proportion of Participants with Testosterone Concentrations ≥ 50 ng/dL at Baseline (Day 1), Mid-Treatment (Treatment Cycle that Most Closely Corresponds to Week 7 of the Primary Study Treatment Period), and Week 13

    Part 3

    Time frame: Baseline (Day 1), Mid-Treatment (Treatment Cycle that Most Closely Corresponds to Week 7 of the Primary Study Treatment Period), and Week 13

  7. Relugolix Concentrations at Baseline (Day 1), In-Cycle, Mid-Treatment, and Week 13 in Each Infusion Cycle for Docetaxel

    Part 3

    Time frame: Baseline (Day 1), In-Cycle, Mid-Treatment, and Week 13 in Each Infusion Cycle for Docetaxel

  8. Docetaxel Concentrations at Baseline (Day 1), In-Cycle, Mid-Treatment, and Week 13 in Each Infusion Cycle for Docetaxel

    Part 3

    Time frame: Baseline (Day 1), In-Cycle, Mid-Treatment, and Week 13 in Each Infusion Cycle for Docetaxel

  9. Incidence of Adverse Events

    Parts 1, 2, and 3

    Time frame: Up to 52 weeks

07

Study locations

16 sites
  • Urological Associates of Southern Arizona, P.C.
    Tucson, Arizona 85741, United States
  • Arkansas Urology
    Little Rock, Arkansas 72211, United States
  • Colorodo Clinical Research
    Lakewood, Colorado 80228, United States
  • Chesapeake Urology Research Associates
    Baltimore, Maryland 21204, United States
  • University of Massachusetts Medical School
    Worcester, Massachusetts 01655, United States
  • New Jersey Urology
    Saddle Brook, New Jersey 07663, United States
  • Clinical Research Alliance, Inc.
    Westbury, New York 11590, United States
  • Alliance Urology
    Greensboro, North Carolina 27403, United States
  • Wake Forest Baptist Health
    Winston-Salem, North Carolina 27157, United States
  • Helios Clinical Research, LLC.
    Middleburg Heights, Ohio 44130, United States
  • Center for Advanced Urology, LLP d/b/a: MidLantic Urology
    Bala-Cynwyd, Pennsylvania 19004, United States
  • Keystone Urology Specialists
    Lancaster, Pennsylvania 17604, United States
  • Carolina Urologic Research Center
    Myrtle Beach, South Carolina 29572, United States
  • Urology Associates, P.C.
    Nashville, Tennessee 37209, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Urology San Antonio
    San Antonio, Texas 78229, United States
08

References and documents

Publications

  • De La Cerda J, Belkoff L, Courtney KD, Diamond E, D'Olimpio J, Dunshee C, Gervasi L, Goodman M, Mittal K, Morris D, Sieber P, Tutrone R, Ryan M, Zhong Y, Ufer M, Shore N. Safety and Tolerability of Relugolix in Combination with Abiraterone or Apalutamide for Treatment of Patients with Advanced Prostate Cancer: Data from a 52-Week Clinical Trial. Target Oncol. 2025 May;20(3):503-517. doi: 10.1007/s11523-025-01139-3. Epub 2025 Apr 4. PubMed 40180682 ↗
  • De La Cerda J, Dunshee C, Gervasi L, Sieber P, Belkoff L, Tutrone R, Lu S, Gatoulis SC, Brown B, Migoya E, Shore N. A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate Cancer. Target Oncol. 2023 May;18(3):383-390. doi: 10.1007/s11523-023-00967-5. Epub 2023 Apr 15. PubMed 37060432 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in May 2024, 39 months.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's 39 months is close to that.

Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2020
First posted
Dec 14, 2020
StartActual
Feb 18, 2021
Primary completionActual
May 28, 2024
CompletionActual
May 28, 2024
Last update
Aug 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04666129
Responsible party
Sponsor
First posted
Dec 14, 2020
Start date
Feb 18, 2021
Primary completion
May 28, 2024
Completion
May 28, 2024
Last update
Aug 17, 2025

Study contacts

Mike Ufer
study director · Sumitomo Pharma America, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Abiraterone · Prednisone · Apalutamide · Docetaxel

Start the discussion